Erratum.

内容摘要

In the article "Pediatric Endocrine Society Annual Meeting (PES 2025), National Harbor, MD, USA, May 15-18, 2025: Abstracts" [Horm Res Paediatr. 2025;98(suppl 3):4-348; https://doi.org/10.1159/000549079], two abstracts were not correctly published in error by the conference organizers. The organizers apologize for the inconvenience and provide the two aforementioned abstracts below.PosterAbstract 1420THE UTILITY OF GROWTH VELOCITY DATA IN DETERMINING THE SEVERITY OF IDIOPATHIC GROWTH HORMONE DEFICIENCYRohan Henry, MD, MS, Nationwide Children's Hospital; Leena Mamilly, MD, Nationwide Children's Hospital; Monika Chaudhari, MD; Amy Pyle-Eiolola, PhD, Nationwide Children's HospitalBackground/Objectives: It is believed by some that growth hormone (GH) secretion exists on a continuum. As such, classification of idiopathic growth hormone deficiency seen as the most common etiology of growth hormone deficiency (GHD), include classical or partial based on severity as defined by peak stimulated growth hormone levels (pGH). Though response to GH therapy is purported to be commensurate with GHD severity, this hypothesis has not been tested. The study aims to determine if there is a difference in GH therapeutic response of GHD cases as defined by growth velocity (GV) based on peak stimulated growth hormone (pGH) levels and MRI findings. Retrospective chart review of GHD cases diagnosed between 3 and 16 years according to GHD severity (pGH <5, 5-7.4 and 7.5-9.9). GV was determined for patients immediately prior to beginning GH therapy, 6-9 months after initiation of GH therapy, and 12-18 months after initiation of GH therapy. Patient's sex, MRI findings, and pubertal status were ascertained. Pre-pubertal was defined as <9.7 years for females and <10.5 years for males. Differences in GV between groups were analyzed by t test and analysis of variance (ANOVA). p values <0.05 were considered significant. The study included 399 children who were diagnosed with GHD and consisted of 292 males and 107 females. Of this, peak GH levels <5, 5-7.4 and 7.5-9.9 ng/mL groups consisted of 116 (79.5%), 85 (75.2%), and 107 (76.4%) males, respectively. Overall, GVs increased by 6-9 months (mean: 9.29 cm/yr, SD: 3.5 cm/yr) and 12-18 months (mean: 8.67 cm/yr, SD: 3.3 cm/yr) post GH therapy when compared to pre-GH therapy (mean: 3.89 cm/yr, SD: 2.2 cm/yr), p < 0.001. However, there was no difference in GV by sex, pre-GH therapy, 6-9 months and 12-18 months post-GH therapy between these groups and also based on MRI findings (pre- and post-pubertal). While GV improves at 6-9 and 12-18 months post-GH therapy in GHD cases based on pGH, GH response is not a valid surrogate for determining GHD severity. In addition, specific MRI finding does not determine therapeutic response to GH.PosterAbstract 1439PSYCHOMETRIC PROPERTIES OF QOLISSY QUESTIONNAIRE IN TURNER SYNDROME - A CROSS-SECTIONAL STUDYNandini Vijayakanthi, MBBS DNB, Wake Forest University/Atrium Health Wake Forest Baptist/Brenner Children's Hospital; David Marcus, PhD, Children's Healthcare of Atlanta; Sobha Fritz, PhD, Emory University School of Medicine/Children's Healthcare of Atlanta; Yijin Xiang, MPH, Emory University School of Medicine; Doris Fadoju, MD, Emory University School of Medicine/Children's' Healthcare of AtlantaShort stature is a major feature in Turner syndrome (TS). The impact on quality of life (QoL) in adolescents/adults with TS have largely been studied using generic QoL questionnaires not short stature-specific questionnaires. In this study, we aimed to assess the psychometric properties of a short stature specific questionnaire - Quality of Life in Short Stature Youth (QoLISSY) in girls with TS.Participants with a karyotype-proven diagnosis of TS were included in our study after they had attained final adult height. English and Spanish gender-specific (female version) QoLISSY questionnaires for adolescents (13-18 years) and the parent version were used to assess the psychometric properties of the questionnaire in this study population (TS). The adolescent version consists of 22 Likert-scaled items assigned to the 3 core QoL dimensions: physical, social, emotional, and 28 additional items reflecting three predictors of QoL: Coping, Beliefs and Treatment (growth hormone therapy). The parent questionnaire consists of 16 additional items on effects of treatment and future dimensions. All scores were transformed from raw scores to 0-100 scores with higher values representing higher QoL.Of the 41 eligible participants, 37 participants were enrolled. The mean age of our cohort was 16.3&#xb1;1.3 years. Compared to reference short stature mean values, our cohort had comparable scores in most QoL subscales and total scores in both parent and participant reports. All of the QoLISSY subscales (except the participant-reported beliefs subscale) had a Cronbach's alpha of >0.70 indicating good internal consistency. Pearson's correlation coefficient (r) showed moderate (r > 0.3) to strong (r > 0.5) positive correlations among most of the QoLISSY subscales and the total score in both parent and participant reports (Table 1). Strong positive correlations were found between the parent report and the participant reports (r = 0.83).The short stature-specific QoLISSY questionnaire could be a valuable tool in assessing QoL with respect to short stature in girls with TS with good internal consistency and strong positive correlations.